NFKB1 and immune system disorder: In the future, pharmacological inhibitors of NF-κB activation may be an attractive therapeutic tool for reducing B cell numbers in BENTA patients but must be approached with caution to avoid exacerbating underlying T/NK cell immunodeficiency.